Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
Hagens Berman Sobol Shapiro LLP alerts investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) to the April 26, 2019 Lead Plaintiff deadline in the securities class action pending in the U.S. District Court for the Eastern District of New York.
If you purchased or otherwise acquired shares of VNDA between November 4, 2015 and February 11, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing VNDA@hbsslaw.com.
According to the complaint, during the class period Defendants misled investors about (1) Vanda’s engagement in a fraudulent scheme in which it promoted the off-label use of 2 drugs (Fanapt and Hetlioz), (2) Vanda’s fraudulent receipt of drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs, and (3) Vanda’s use of misleading promotional materials for the drugs.
“We’re focused on investors’ losses, matters raised in the recently unsealed whistleblower complaint, and the FDA’s apparent view that the Company used improper promotional materials,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.